TY - JOUR
T1 - Effect of genetic polymorphisms related to DNA repair and the xenobiotic pathway on the prognosis and survival of gastric cancer patients
AU - Tahara, Tomomitsu
AU - Shibata, Tomoyuki
AU - Nakamura, Masakatsu
AU - Yamashita, Hiromi
AU - Yoshioka, Daisuke
AU - Okubo, Masaaki
AU - Yonemura, Joh
AU - Ishizuka, Takamitsu
AU - Maruyama, Naoko
AU - Kamano, Toshiaki
AU - Kamiya, Yoshio
AU - Fujita, Hiroshi
AU - Nakagawa, Yoshihito
AU - Nagasaka, Mitsuo
AU - Iwata, Masami
AU - Yamada, Hideto
AU - Hirata, Ichiro
AU - Arisawa, Tomiyasu
PY - 2011/2
Y1 - 2011/2
N2 - Background: A number of association studies have focused on the effect of polymorphisms related to DNA repair or the xenobiotic pathway, on the susceptibility to gastric cancer (GC). Here, the possible association between common polymorphisms in the X-ray repair cross-complementing groups (XRCC) 1, and glutathione-S-transferase (GST) genes and various clinicopathological characteristics, including overall survival, in GC patients were evaluated. Patients and Methods: XRCC1 Arg399Gln, and Arg194Trp, GSTP1 Ile104Val, and GSTT1, GSTM1 null polymorphisms were determined in 130 GC patients. Results: XRCC1 codon 194 Trp carriers (Trp/Trp + Arg/Trp) held a significantly higher risk of venous invasion (OR=3.76, 95%CI=1.05-13.51, p=0.043). A similar trend was also found for the XRCC1 codon 194 TrplTrp genotype (OR=2.15, 95% CI=0.87-5 34, p=0.099). The frequencies of the XRCC1 codon 399 Gln/Gln and Arg/Gln genotypes tended to be lower in lymphatic invasion-positive GC (XRCC1 codon 399 Gln/Gln: OR=0.27, 95% CI=0.06-1.15, p=0.075, Gln/Gln + Arg/Gln: OR=0.46, 95% CI=0.20-1.06, p=0.069), while the frequencies of the XRCC1 codon 194 Trp/Trp genotype tended to be higher in lymphatic invasion-positive GC (XRCC1 codon 194 Trp/Trp: OR=7.70, 95% CI=0.95-62.60, p=0.056). The patients with the GSTT1 null genotype showed significantly better overall survival than the patients with the GSTT1 present genotype (p=0.019). Conclusion: XRCC1 codon 194 Trp carrier status is correlated with more aggressive biological behavior of GC, such as venous invasion, and the GSTT1 null genotype is associated with better survival in GC patients.
AB - Background: A number of association studies have focused on the effect of polymorphisms related to DNA repair or the xenobiotic pathway, on the susceptibility to gastric cancer (GC). Here, the possible association between common polymorphisms in the X-ray repair cross-complementing groups (XRCC) 1, and glutathione-S-transferase (GST) genes and various clinicopathological characteristics, including overall survival, in GC patients were evaluated. Patients and Methods: XRCC1 Arg399Gln, and Arg194Trp, GSTP1 Ile104Val, and GSTT1, GSTM1 null polymorphisms were determined in 130 GC patients. Results: XRCC1 codon 194 Trp carriers (Trp/Trp + Arg/Trp) held a significantly higher risk of venous invasion (OR=3.76, 95%CI=1.05-13.51, p=0.043). A similar trend was also found for the XRCC1 codon 194 TrplTrp genotype (OR=2.15, 95% CI=0.87-5 34, p=0.099). The frequencies of the XRCC1 codon 399 Gln/Gln and Arg/Gln genotypes tended to be lower in lymphatic invasion-positive GC (XRCC1 codon 399 Gln/Gln: OR=0.27, 95% CI=0.06-1.15, p=0.075, Gln/Gln + Arg/Gln: OR=0.46, 95% CI=0.20-1.06, p=0.069), while the frequencies of the XRCC1 codon 194 Trp/Trp genotype tended to be higher in lymphatic invasion-positive GC (XRCC1 codon 194 Trp/Trp: OR=7.70, 95% CI=0.95-62.60, p=0.056). The patients with the GSTT1 null genotype showed significantly better overall survival than the patients with the GSTT1 present genotype (p=0.019). Conclusion: XRCC1 codon 194 Trp carrier status is correlated with more aggressive biological behavior of GC, such as venous invasion, and the GSTT1 null genotype is associated with better survival in GC patients.
UR - http://www.scopus.com/inward/record.url?scp=79953235148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953235148&partnerID=8YFLogxK
M3 - Article
C2 - 21378360
AN - SCOPUS:79953235148
SN - 0250-7005
VL - 31
SP - 705
EP - 710
JO - Anticancer research
JF - Anticancer research
IS - 2
ER -